TG THERAPEUTICS, INC. Net Change in Cash
TG THERAPEUTICS, INC. (TGTX) reported Net Change in Cash of $403.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-05
- TG THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $363.07M.
- TG THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$47.75M.
- TG THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$17.45M.
- TG THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$40.83M.
- TG THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$100.70M, a 215.78% decline from fiscal 2024.
- TG THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $86.97M.
- TG THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$9.36M.
- TG THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$196.57M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $403.45M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $363.07M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$100.70M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | -$105.78M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | -$50.75M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | -$47.75M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $86.97M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $102.90M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | -$10.02M 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | -$17.45M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$9.36M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $48.61M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$5.29M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | -$40.83M 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$196.57M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | -$189.02M 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | -$151.81M 10-Q · filed 2023-08-04 | |||
| 2022-03-31 | -$113.21M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$254.55M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | -$226.92M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$151.73M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$81.92M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $440.81M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $141.52M 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | $147.88M 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | -$60.58M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $70.69M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $2.72M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $15.28M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $22.39M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$14.11M 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $31.69M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |